Open-access Syndromic Surveillance Study in Northeast Brazil Identifies SARS-CoV-2 Coinfection with Other Respiratory Pathogens and Analyzes Their Clinical Associations

Abstract

Acute febrile respiratory infections may be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory pathogens (ORPs). Understanding the prevalence of coinfection and its associated factors is essential for improved surveillance and patient management. This retrospective cross-sectional study used data from sentinel surveillance in Pernambuco, Northeast Brazil, from August 2021 to December 2022. SARS-CoV-2 and 26 ORPs were detected using multiplex reverse transcription quantitative polymerase chain reaction (RT-qPCR) assays. Sociodemographic and clinical data were retrieved from the REDCap database to assess prevalence and analyze factors associated with coinfection using multiple logistic regression. A total of 772 symptomatic individuals were tested, of whom 55.8% presented monoinfections and 11% coinfections, with SARS-CoV-2 being the most prevalent agent. Haemophilus influenzae (42.6%) and coronavirus 229E (14.8%) were the most frequent co-pathogens among SARS-CoV-2–coinfected cases. No demographic or comorbidity differences were observed between groups. Dysgeusia was identified as the only factor independently associated with coinfection (aOR=2.20; 95% CI: 1.19–3.99; p=0.0101). The model showed moderate accuracy (AUC=0.61) and robustness (E-value=1.84). Dysgeusia was identified as an independent clinical marker of respiratory coinfection, underscoring its diagnostic and surveillance value and highlighting the importance of multiplex molecular testing to strengthen public health preparedness.

Key words
Acute febrile syndrome; Coinfection; Respiratory Pathogens; Surveillance

INTRODUCTION

In 2020, a novel respiratory virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in Wuhan, China, spread rapidly worldwide. In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic (WHO 2020). In Brazil, the pandemic had a disproportionate impact on the North and Northeast regions. Specifically, in the state of Pernambuco, an ecological study based on surveillance data showed that, during the pre-pandemic period (2015–2019), an average of 187 cases of Severe Acute Respiratory Infection (SARI) were reported per month, corresponding a semiannual rate of 23.8 cases per 100,000 inhabitants; during the early stage of the COVID-19 pandemic, this number rose to an average of 2,517 cases/month (320.3 cases/100,000 inhabitants), an approximately 13-fold increase, with marked spatial disparities among the state’s Health Regions (Silva et al. 2020).

Since the onset of the pandemic, extensive research has been conducted to understand the COVID-19 and its pathophysiology. Evidence has suggested that the co-detection of other respiratory pathogens (ORPs) may be a risk factor for greater disease severity (Cox et al. 2020, Singh et al. 2021, Feldman & Anderson 2021). Early reports from China identified few coinfections involving SARS-CoV-2 and ORPs; however, subsequent studies have indicated that coinfection rates may be higher than initially reported (Westblade et al. 2021, Morales-Jadán et al. 2023).

Understanding the epidemiology and transmission dynamics of respiratory pathogens is essential for their timely detection and for informing public health strategies aimed at outbreak management and reducing the burden of respiratory infections (Hughes et al. 2016, Kim et al. 2019). Studies have highlighted the concurrent detection of SARS-CoV-2 and ORPs, including influenza A (H1N1), in both children and adults, underscoring the importance of multiplex molecular panels within syndromic surveillance systems (Fahim et al. 2021, Essaidi-Laziosi et al. 2022, Uhteg et al. 2022).

In this context, given the limited data on respiratory pathogen coinfection and its clinical correlates in Northeast Brazil, this study aimed to estimate the prevalence of respiratory pathogens, identify factors associated with monoinfection and coinfection, and characterize the clinical profiles of adults presenting with influenza-like illness in Recife, Pernambuco, Brazil. By addressing this knowledge gap, the study seeks to contribute evidence relevant to molecular syndromic surveillance and respiratory infection monitoring.

MATERIALS AND METHODS

Study area

Data for all diagnostic tests and the clinical information of suspected cases were collected as part of routine work at the basic health units of the Recife, located in the state of Pernambuco, in the northeast region of Brazil (Figure 1). Data were collected from August 2021 to December 2022. Recife is divided into 8 health districts (DS), comprising 93 neighborhoods. Participants were recruited from COVID-19 reference units located on seven of these DSs, which together covered 87 neighborhoods. The remaining district had no sentinel unit due to the municipal network structure, and its residents were referred to the nearest participating site.

Figure 1
Geographical distribution of the sentinel surveillance units across the health districts of Recife, located in the state of Pernambuco, in the northeast region of Brazil.

Case definition

Individuals aged 18 years or older who sought care at participating sentinel health units and reported at least one acute respiratory symptom, including fever, headache, cough, body aches, or sore throat, were considered eligible. This intentionally sensitive case definition was adopted within the syndromic surveillance framework to capture the heterogeneous clinical presentations of acute respiratory infections.

Study design and sample collection

This cross-sectional syndromic surveillance study was conducted in sentinel units. Participants were recruited through convenience sampling among symptomatic adults seeking care at primary healthcare facilities designated as COVID-19 reference units within the sentinel surveillance network of Recife. No active community-based recruitment was performed. After receiving information, those who agreed to participate were invited to join the study. Participants were enrolled after providing written informed consent. Sociodemographic and clinical data, including comorbidities and signs and symptoms, were collected using semi-structured questionnaires. Biological samples were obtained through nasopharyngeal swabs and venous blood collection.

Molecular Detection of SARS-CoV-2 and Other Respiratory Pathogens

Infection status was subsequently determined through molecular testing and did not rely on self-reported symptoms. SARS-CoV-2 infections were diagnosed in participants’ nasopharyngeal samples by real-time reverse transcription PCR (RT-qPCR) testing, using the Duplex SARS-CoV-2 E/RP Molecular Kit (Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil) in accordance with the previously-described protocol. Infection cases for ORPs were diagnosed using the Allplex™ Respiratory Panel Assays, a one-step multiplex real-time RT-PCR system (Seegene Inc., Seoul, Republic of Korea), which enables the detection of 27 respiratory pathogens (Supplementary Material - Table SI) across four panels. Panel 1 detects influenza A virus, influenza B virus, respiratory syncytial virus (RSV) A, RSV B, and certain subtypes of influenza A virus (influenza A subtypes H1, H3, and H1pdm09). Panel 2 detects human adenovirus, human metapneumovirus, human enterovirus, human parainfluenza virus 1, human parainfluenza virus 2, human parainfluenza virus 3, and human parainfluenza virus 4. Panel 3 detects human bocavirus 1/2/3/4, human rhinovirus A/B/C, human coronavirus 229E, human coronavirus NL63, and human coronavirus OC43. Panel 4 detects Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Bordetella pertussis, Bordetella parapertussis, Streptococcus pneumoniae, and Haemophilus influenzae. RNA extraction was performed automatically using the Maxwell® RSC 48 Instrument (Promega Corporation, Madison, WI, USA). RT-qPCR was performed for the ORP panel on the CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Samples were considered positive when Ct ≤ 42 and negative when Ct > 42, following the manufacturer-defined interpretation criteria embedded in the Allplex™ automated analysis software (Seegene Viewer/CFX Manager; Seegene Inc., Seoul, Republic of Korea), as specified in the Instructions for Use of the Allplex™ Respiratory Panel Assays. Coinfections were assessed on the same respiratory sample.

Data Analysis

Sociodemographic and clinical data, including comorbidities and signs and symptoms, were retrospectively retrieved from the REDCap database. Monoinfection was defined as the detection of a single respiratory pathogen, including either SARS-CoV-2 or another respiratory pathogen. Coinfection was defined as the simultaneous detection of two or more respiratory pathogens in the same sample. This classification was adopted to evaluate respiratory coinfection broadly within the syndromic surveillance population, rather than restricting the analysis to SARS-CoV-2-positive cases. To evaluate associations between coinfection status, clinical presentation, and participant characteristics, the outcome variable for the logistic regression model was defined as coinfection (presence of ≥ 2 pathogens), and the control (reference) group (absence of coinfection) consisted of patients with monoinfections of either SARS-CoV-2 or ORP. Statistical analyses were carried out using R (version 4.4.1) (R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS Statistics (version 20). Qualitative variables are presented as percentages. Bivariate analysis was conducted using the Chi-square test or Fisher’s exact test as appropriate, in conjunction with multiple logistic regression. To investigate the potential factors associated with the likelihood of coinfection with SARS-CoV-2 and ORPs, a multiple logistic regression model was employed. Coinfection was coded as the outcome category, and monoinfection was used as the reference category. Therefore, adjusted odds ratios greater than 1 indicated higher odds of coinfection. Variables with clinical relevance were included in the full model. The Stepwise Mixed selection procedure (direction = “both”) was then applied, utilizing the Akaike Information Criterion (AIC) to obtain the final, most parsimonious adjusted model, controlling for measured confounding. The quality of the final model’s fit and predictive power was assessed using the ROC Curve and the Area Under the Curve (AUC), and multicollinearity was checked using the Variance Inflation Factor (VIF). The results were presented as an Adjusted Odds Ratio (aOR) with a 95% confidence interval (CI). Furthermore, the E-value was calculated for all statistically significant associations to formally quantify the resilience of the findings against unmeasured confounding bias. A p-value of ≤ 0.05 was considered statistically significant.

Ethical Statement: The study was approved by the Ethics Committee of the Federal University of Pernambuco (CAEE: 71530423.3.0000.5208).

RESULTS

A total of 772 individuals presenting with symptoms suggestive of a respiratory infection were recruited and tested for the presence of SARS-CoV-2 and ORPs.

An analysis of the sociodemographic characteristics of the sample revealed a higher proportion of women (71%) and individuals with brown skin (44%) (Table I). Regarding clinical presentation, the most frequent signs and symptoms reported across the entire sample (N=772) were: cough (79%), headache (76%), sore throat (76%) and runny nose (74%). The frequencies of the other reported symptoms, such fever (54%), fatigue (47%), drowsiness (43%), myalgia (42%), and arthralgia (25%) are detailed in Table I. The remaining 25 clinical aspects pertaining to signs and symptoms are presented in the supplementary materials (Table SII).

Table I
Sociodemographic and clinical profile of cases suspected of SARS-CoV-2 and/or other respiratory pathogens infection (n = 772).

Of the total sample, 516 (66.9%) tested positive for at least one pathogen. For the analyses, monoinfection was defined as the detection of a single respiratory pathogen, whereas coinfection was defined as the simultaneous detection of two or more respiratory pathogens in the same sample, regardless of whether SARS-CoV-2 was present.

Among the 516 pathogen-positive participants, we observed a total of 431 monoinfections (83.5%) and 85 coinfections (16.5%). Overall, SARS-CoV-2 was a prevalent agent, being detected in monoinfection cases (47%, n=245) and coinfection cases (11%, n=54), compared to ORPs alone in monoinfection (36%, n=186) and coinfection (6%, n=31) (Table II). Of the suspected cases, 256 (33.1%) tested negative for all 27 respiratory pathogens investigated, indicating that the tested negative for all investigated pathogens. Considering these results, five groups of analysis were established in accordance with the categorization specifications outlined in Table II.

Table II
Frequencies of symptomatic cases (n = 772) categorized by infection status. The symptomatic cases were categorized based on the number of positive infections for SARS-CoV-2 and other respiratory pathogens. The negative symptomatic cases group includes individuals who were not molecularly diagnosed with any of the pathogens in the panels. ORPs comprise all respiratory pathogens included in the multiplex molecular panels, excluding SARS-CoV-2. Monoinfection was defined as the detection of a single pathogen, whereas coinfection was defined as the simultaneous detection of two or more pathogens in the same sample. The complete list of ORPs is provided in Table SI.

SARS-CoV-2 monoinfections were the most frequent (32%, n=245). Considering the 54 SARS-CoV-2-infected participants with coinfection, Haemophilus influenzae was the most frequent co-agent (42.6%, n=22), followed by coronavirus 229E (14%, n=8) (Table III). In cases of monoinfection involving only ORPs (Group B), Rhinovirus (35%, n=65), Haemophilus influenzae (25%, n=47), coronavirus 229E (8%, n=15), influenza A-H3 (6%, n=12), metapneumovirus (6%, n=12), RSV (5%, n=9), parainfluenza virus (5%, n=9), Streptococcus pneumoniae (4%, n=8), enterovirus (2%, n=3), coronavirus OC43 (2%, n=3), bocavirus (1%, n=2), and adenovirus (1%, n=1) were detected. Fifteen respiratory pathogens were not detected during the period evaluated. In cases of coinfection of ORPs (without SARS-CoV-2) (Group D), there was a higher frequency of the bacterium Haemophilus influenzae (61%, n=19) in the coinfection panels. Other ORPs were detected including rhinovirus, Streptococcus pneumoniae, metapneumovirus, RSV, influenza A-H3, and the viruses enterovirus, coronavirus OC43, coronavirus 229E, coronavirus NL63, and adenovirus. Triple coinfection was detected in two individuals (Table III).

Table III
Summary of coinfections (n = 85) detected among symptomatic individuals. Coinfections are represented by the abbreviations of the pathogens involved, the total number of pathogens per coinfection, and their relative and absolute frequencies. Percentages were calculated using the total number of coinfections involving SARS-CoV-2 (n = 54) as the denominator for SARS-CoV-2–associated coinfections and the total number of coinfections involving only other respiratory viruses (n = 31) as the denominator for the remaining coinfections.

When the clinical and sociodemographic profiles of SARS-CoV-2 and/or ORP monoinfection cases versus coinfection cases were compared, the presentation of signs and symptoms in monoinfection cases versus coinfection cases revealed that the anosmia (24.7% vs 15.1%; p=0.030) and dysgeusia (24.7% vs. 14.6%; p = 0.021) were significantly associated with individuals diagnosed with coinfection (Table IV). No statistically significant differences were observed in histories of previous comorbidities when monoinfection cases were compared with coinfection cases (Table IV).

Table IV
Clinical profile, including signs, symptoms, and clinical history (comorbidities), categorized by cases of mono-infection and coinfection with respiratory pathogens.

The logistic regression model was constructed to consider coinfection as the outcome variable and monoinfection as the reference category. In the adjusted logistic regression model, dysgeusia was the only factor independently associated with higher odds of coinfection (aOR = 2.20; 95% CI: 1.19–3.99; p = 0.0101). Anosmia was not retained in the final model.

The final adjusted model, obtained through the Stepwise Mixed selection procedure, demonstrated stability, with all Variance Inflation Factor (VIF) values being close to 1.0 (ranging from 1.02-1.13). The model’s overall discriminatory power was modest, yielding an AUC of 0.608 (Figure S1).

After investigation of associated factors with the likelihood of coinfection, the adjusted logistic regression model identified dysgeusia was the only factor independently associated with higher odds of coinfection (Adjusted OR = 2.20, 95% CI: 1.19-3.99; p = 0.0101). Anosmia was not retained in the final model. No other signs or symptoms, including diabetes mellitus, and dyspnea, reached the threshold for statistical significance (Figure 2 and Table V). Furthermore, the robustness of this primary finding against unmeasured confounding bias was formally quantified using the E-Value. The association between dysgeusia and coinfection demonstrated strong resilience, with an E-value for the lower bound of the 95% CI of 1.84. This suggests that an unmeasured confounder would have to be associated with both coinfection and loss of taste by an OR of at least 1.84 (each) to fully eliminate the statistical significance of our finding (Table V).

Table V
Logistic regression model of factors associated with SARS-CoV-2 coinfection with other respiratory pathogens. Adjusted odds ratios (aORs), 95% confidence intervals (CIs), p-values, and E-values are presented. E-values estimate the minimum strength of association required for an unmeasured confounder to explain away the observed association.
Figure 2
Forest plot of adjusted odds ratios (aOR) with 95% confidence intervals for factors associated with respiratory coinfection. The multivariate logistic regression model was obtained through mixed stepwise selection (AIC criterion). The plot displays the magnitude and direction of associations between clinical and demographic variables and the presence of coinfection, with the vertical line indicating the null value (aOR = 1).

DISCUSSION

Studies suggest that syndromic surveillance can accurately predict outbreaks of respiratory pathogens based on geographic location and temporal patterns (Maharaj et al. 2021, Uhteg et al. 2022, Morales-Jadán et al. 2023). Morales-Jadán et al. (2023) emphasized the importance of monitoring respiratory pathogen activity through syndromic surveillance to detect the onset of pathogen circulation throughout the year and to implement timely measures. They also highlighted the value of using broad-spectrum molecular diagnostic panels for rapid detection of coinfections or secondary infections with other respiratory pathogens, which contributes to more effective surveillance.

The emergence of SARS-CoV-2 has likely affected the seasonality of other respiratory pathogens. Ramirez Varela et al. (2021) observed that, among 1,435 symptomatic participants, no cases of RSV or influenza were detected, while SARS-CoV-2 was detected in 32.7% of the patients. Similar observations were reported in Israel, Australia, South Africa, New Zealand, France, the United States, and Japan (Chuang et al. 2023). In our study, which included samples collected from August 2021 to December 2022, we also observed low frequencies of RSV and influenza, both of which typically exhibit seasonal peaks during the winter in Brazil. Likewise, other viruses that circulate year-round, such as adenovirus, human bocavirus, and human metapneumovirus, also showed low frequencies in our results.

Analysis of clinical signs and symptoms revealed that dysgeusia was associated with coinfection status of SARS-CoV-2 and/or ORPs, whereas other neurosensory symptoms were not. However, the symptom profile of coinfected patients in our study differs from that reported by Krumbein et al. (2023), who identified chills, dizziness, wheezing, and abdominal pain as the most frequent symptoms among coinfected individuals. The divergence observed in the profile of signs and symptoms between the studies may be explained by differences in the populations investigated and in the temporal scope of the research. While our study focused exclusively on adult individuals, the systematic review conducted by Krumbein et al. (2023) included twenty-nine studies involving adult populations and five studies that assessed only pediatric patients. This age-related heterogeneity may substantially influence clinical presentation and, consequently, account for the discrepancies identified.

Moreover, Krumbein et al. (2023) found that anosmia and dysgeusia were more prevalent in patients with SARS-CoV-2 monoinfection, which is consistent with the known neurotropism of SARS-CoV-2 and the concentration of systemic symptoms in our coinfected group.

Regarding the distribution of ORPs in our study, rhinovirus and Haemophilus influenzae were frequently detected. Studies by Krumbein et al. (2023) and Maltezou et al. (2023), which involved extensive systematic reviews and meta-analyses conducted in Asia, Europe, and North America, corroborated our findings regarding rhinovirus. In our study, multiplex molecular testing identified SARS-CoV-2 co-detection with ORPs; with H. influenzae being the most frequently detected bacterial target among these cases. However, because nasopharyngeal molecular detection cannot distinguish colonization from active infection, these findings should be interpreted as bacterial co-detection rather than confirmed bacterial coinfection. To the best of our knowledge , data on H. influenzae co-detection among non-hospitalized SARS-CoV-2 positive adults in Latin America remains scarce. These findings are consistent with previous reports describing bacterial co-detection in individuals with SARS-CoV-2 infection (Bordi et al. 2020, Zhang et al. 2020), although direct comparisons should be made cautiously because of differences in study populations and diagnostic methods.

The main limitations of this study stem from its cross-sectional design and restricted geographical scope, which limit causal inference and generalizability. Because participant eligibility and clinical characteristics were based partly on self-reported symptoms, recall and reporting bias cannot be excluded. However, symptoms were collected at enrolment using a standardized questionnaire, and infection status was independently established through molecular testing. Although the model showed high internal stability (low VIF) and the main association remained robust, its overall discriminatory power was modest, reflecting the complexity of infectious outcomes and the possible influence of unmeasured confounders such as host genetics or pathogen load. Although the detection of Haemophilus influenzae DNA in nasopharyngeal samples may reflect colonization rather than active infection, its detection may nevertheless have clinical relevance, as bacterial carriage or coinfection could be associated with poorer patient outcomes. Despite these limitations, this work provides a statistically sound reference and addresses an important knowledge gap in understanding coinfection dynamics within an underrepresented region.

Ultimately, this study underscores the value of simple and accessible clinical markers for supporting respiratory coinfection assessment. By identifying dysgeusia as the only factor independently associated with respiratory coinfection. Our findings offer a preliminary, exploratory signal that may complement broader diagnostic or syndromic evaluation, particularly in low-resource settings. This finding constitutes a mechanistic hypothesis that warrants targeted, prospective validation to determine its clinical utility and to elucidate the biological pathways underlying the pathogenesis of respiratory coinfection.

CONCLUSIONS

Our findings, based on data collected during the COVID-19 pandemic period, reveal that dysgeusia emerged as the only factor independently associated with respiratory coinfection in the current model, after adjustment for major clinical and demographic confounders. These findings highlight dysgeusia as clinical marker of viral coinfection and support its inclusion in diagnostic and surveillance protocols. Furthermore, the use of a multiplex panel may hold great importance for effective syndromic surveillance, offering considerable implications for public health policies and strategies.

SUPPLEMENTARY MATERIAL

Acknowledgements

Authors thanks to the Pan American Health Organization, the Secretaria de Saúde do Recife (SESAU) for the partnership, granting us access to sentinel health units.

Data availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to ethical approval and applicable data protection requirements.

Declaration of Use of Artificial Intelligence

During the preparation of this study, the authors used the ChatGPT 5.6 (OpenAI) as a technical support tool for reviewing the English language and assisting with the development and debugging of R code. After using AI, all generated content was rigorously reviewed, edited, and validated by the authors before its use. The authors assume full responsibility for the originality, integrity, and accuracy of the information presented in this manuscript.

References

  • BORDI L, NICASTRI E, SCORZOLINI L, DI CARO A, CAPOBIANCHI MR, CASTILLETTI C & LALLE E. 2020. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill 25: 2000170.
  • CHUANG YC, LIN KP, WANG LA, YEH TK & LIU PY. 2023. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist 16: 661-675.
  • COX MJ, LOMAN N, BOGAERT D & O’GRADY J. 2020. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe 1: e11.
  • ESSAIDI-LAZIOSI M, ALVAREZ C, PUHACH O, SATTONNET-ROCHE P, TORRIANI G, TAPPAREL C, KAISER L & ECKERLE I. 2022. Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract. Emerg Microbes Infect 11: 412-423.
  • FAHIM M, GHONIM HAES, ROSHDY WH, NAGUIB A, ELGUINDY N, ABDELFATAH M, HASSANY M, MOHSEN A, AFIFI S & EID A. 2021. Coinfection with SARS-CoV-2 and influenza A(H1N1) in a patient seen at an influenza-like illness surveillance site in Egypt: case report. JMIR Public Health Surveill 7: e27433.
  • FELDMAN C & ANDERSON R. 2021. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia 13: 5.
  • HUGHES HE, MORBEY R, HUGHES TC, LOCKER TE, PEBODY R, GREEN HK, ELLIS J, SMITH GE & ELLIOT AJ. 2016. Emergency department syndromic surveillance providing early warning of seasonal respiratory activity in England. Epidemiol Infect 144: 1052-1064.
  • KIM TH, HONG KJ, SHIN SD, PARK GJ, KIM S & HONG N. 2019. Forecasting respiratory infectious outbreaks using ED-based syndromic surveillance for febrile ED visits in a Metropolitan City. Am J Emerg Med 37: 183-188.
  • KRUMBEIN H, KÜMMEL LS, FRAGKOU PC, THÖLKEN C, HÜNERBEIN BL, REITER R, PAPATHANASIOU KA, RENZ H & SKEVAKI C. 2023. Respiratory viral co-infections in patients with COVID-19 and associated outcomes: a systematic review and meta-analysis. Rev Med Virol 33: e2365.
  • MAHARAJ AS ET AL. 2021. The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada. Lancet Infect Dis 21: 593-594.
  • MALTEZOU HC, PAPANIKOLOPOULOU A, VASSILIU S, THEODORIDOU K, NIKOLOPOULOU G & SIPSAS NV. 2023. COVID-19 and respiratory virus co-infections: a systematic review of the literature. Viruses 15: 865.
  • MORALES-JADÁN D, MUSLIN C, VITERI-DÁVILA C, CORONEL B, CASTRO-RODRÍGUEZ B, VALLEJO-JANETA AP, HENRÍQUEZ-TRUJILLO AR, GARCIA-BEREGUIAIN MA & RIVERA-OLIVERO IA. 2023. Coinfection of SARS-CoV-2 with other respiratory pathogens in outpatients from Ecuador. Front Public Health 11: 1264632.
  • RAMIREZ VARELA A ET AL. 2021. Factors associated with SARS-CoV-2 infection in Bogotá, Colombia: results from a large epidemiological surveillance study. Lancet Reg Health Am 2: 100048.
  • SILVA APSC, MAIA LTS & SOUZA WV. 2020. Severe Acute Respiratory Syndrome in Pernambuco: comparison of patterns before and during the COVID-19 pandemic. Cien Saude Colet 25: 4141-4150.
  • SINGH V, UPADHYAY P, REDDY J & GRANGER J. 2021. SARS-CoV-2 respiratory co-infections: incidence of viral and bacterial co-pathogens. Int J Infect Dis 105: 617-620.
  • UHTEG K, AMADI A, FORMAN M & MOSTAFA HH. 2022. Circulation of non-SARS-CoV-2 respiratory pathogens and coinfection with SARS-CoV-2 amid the COVID-19 pandemic. Open Forum Infect Dis 9: ofab618.
  • WESTBLADE LF, SIMON MS & SATLIN MJ. 2021. Bacterial coinfections in coronavirus disease 2019. Trends Microbiol 29: 930-941.
  • WORLD HEALTH ORGANIZATION. 2020. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. World Health Organization, Geneva.
  • ZHANG G, HU C, LUO L, FANG F, CHEN Y, LI J, PENG Z & PAN H. 2020. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 127: 104364.

Correspondence

Correspondence to: Moacyr Jesus Barreto de Melo Rêgo *contributed equally to this paper

Handling editor

Helton Santiago

Publication Dates

  • Publication in this collection
    20 Nov 2026
  • Date of issue
    2026

History

  • Received
    9 Apr 2026
  • Accepted
    21 Aug 2026
location_on
Academia Brasileira de Ciências Rua Anfilófio de Carvalho, 29, 3º andar, 20030-060 Rio de Janeiro RJ Brasil, Tel: +55 (21) 2391-7901 - Rio de Janeiro - RJ - Brazil
E-mail: aabc@abc.org.br
rss_feed Acompanhe os números deste periódico no seu leitor de RSS
Ir para o topo